Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Cyclin Dependent Kinase Inhibitor 2A (CDKN2A)
No significant cross-reactivity or interference between Cyclin Dependent Kinase Inhibitor 2A (CDKN2A) and analogs was observed.
LS-F4068 is a 96-well enzyme-linked immunosorbent assay (ELISA) for the detection of Mouse CDKN2A / p16INK4a in samples of Tissue Homogenates. It is based upon a Sandwich assay principle and can be used to detect levels of CDKN2A / p16INK4a as low as 0.313 nanograms per millilter.
96-Well Strip Plate
Colorimetric - 450nm (TMB)
0.313 - 20 ng/ml
Intra-Assay: CV<10% Inter-Assay: CV<12%
Due to their limited shelf life, LSBio ELISA kits are not typically stocked as finished goods. Upon receipt of an order each kit is assembled and tested to ensure that it meets specifications before shipping. Minor changes may occur to the Range, Sensitivity, and Precision. In the event of a significant change the order would be confirmed with the customer before shipping ELISA kit lot numbers reflect the date of final assembly and testing for each specific kit rather than a bulk manufactured lot. All kits are tested to confirm that they fall within their defined Inter- and Intra- assay coefficient of variation.
Capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes.